1. Scrip
  2. >>COVID-19

Coronavirus Update: FDA Fast-Tracks Blood Plasma Trials, Novavax Closes In On Vaccine Start

Plus: Japan Accelerates Research As Outbreak Worsens

 
• By Scrip Team

As US cases set to reach half a million, FDA gives green light to blood plasma trials to help meet urgent need for therapies.

Plasma
Blood plasma taken from convalescing patients could help the critically ill • Source: Shutterstock

The US Food and Drug Administration has approved a number of clinical trials to to test blood plasma therapy in COVID-19 patients.

Four US healthcare providers, including Johns Hopkins and the Mayo Clinic, have received FDA approval for the clinical trial, which...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from COVID-19

More from Scrip

BerGenBio Plumps For Oncoinvent From Long List Of 50 Suitors

 
• By Kevin Grogan

The merger with a fellow Norwegian biotech comes a few months after its lead asset, bemcentinib, bit the dust.

In Brief: Opus Gears Up For FDA Filing In Presbyopia

 
• By Sushmita Panda

Data from a second pivotal trial support a filing in the US for Opus Genetics’ phentolamine ophthalmic solution, to treat presbyopia.

BlissBio Goes Solo On HER2-Targeting ADC After Eisai Exit

 
• By Dexter Jie Yan

BlissBio is to single-handedly move BB-1701, its eribulin-containing, HER2-targeting antibody-drug conjugate, into a global pivotal Phase II/III program for HER2-expressing, Enhertu-resistant breast cancer.